



(11) (21) (C) **2,019,218**
(22) 1990/06/18
(43) 1990/12/19
(45) 2001/01/02

(72) Hermentin, Peter, DE

(72) Donges, Reiner, DE

(72) Franssen, Udo, DE

(72) Enssle, Karlheinz, DE

(72) Friesen, Heinz-Jürgen, DE

(73) DADE BEHRING MARBURG GMBH, DE

(51) Int.Cl.⁵ C07F 15/02, A61K 47/48, C12N 5/08, C12N 5/06, C07K 1/14,
C07K 17/00

(30) 1989/06/19 (P 39 19 873.1) DE

(54) **CONJUGATS DE PROTEINE MAGNETIQUES, PROCEDE DE
PREPARATION ET UTILISATION**

(54) **MAGNETIC PROTEIN CONJUGATES, A PROCESS FOR THE
PREPARATION THEREOF AND THE USE THEREOF**

(57) The invention relates to magnetic protein conjugates of the formula I $M-NH-CO-(CH_2)_n-S-P$ with $n = 1-6$, preferably with $n = 1$ or 2 and particularly preferably with $n = 1$, in which M is a dispersible, magnetically reacting material or particle which carries amino groups, and P is a protein, to a process for the preparation thereof and to the use thereof for the specific removal of cells or soluble antigens, receptors, substrates, cofactors or carbohydrate determinants from aqueous salt solutions or body fluids or as part of a diagnostic method or as a diagnostic aid, preferably for the removal of cells, preferably for bone marrow depletion or for HLA typing.

BEHRINGWERKE AKTIENGESELLSCHAFT HOE 89/B 0 26 - Ma 776

Dr. Ha/Sd

Abstract of the disclosure

Magnetic protein conjugates, a process for the preparation thereof and the use thereof

The invention relates to magnetic protein conjugates of the formula I



with $n = 1-6$, preferably with $n = 1$ or 2 and particularly preferably with $n = 1$, in which M is a dispersible, magnetically reacting material or particle which carries amino groups, and P is a protein, to a process for the preparation thereof and to the use thereof for the specific removal of cells or soluble antigens, receptors, substrates, cofactors or carbohydrate determinants from aqueous salt solutions or body fluids or as part of a diagnostic method or as a diagnostic aid, preferably for the removal of cells, preferably for bone marrow depletion or for HLA typing.

BEHRINGWERKE AKTIENGESELLSCHAFT HOE 89/B 0 26 - Ma 776
Dr. Ha/Sd

Description

5 Magnetic protein conjugates, a process for the preparation thereof and the use thereof

The invention relates to magnetic protein conjugates of the formula I



10 with $n = 1-6$, preferably with $n = 1$ or 2 and particularly preferably with $n = 1$, to which the following applies:

M is a dispersible, magnetically reacting material or particle which carries amino groups, and P is a protein.

15 P can be a protein in which one or more sulfhydryl groups are either present in the natural way or generated by reduction of disulfide linkages or introduced by chemical reaction.

20 P is, in particular, an immunoglobulin or immunoglobulin residue, preferably a monoclonal antibody or a Fab, Fab' or F(ab')_2 fragment, an antigen or a residue of an enzyme, hormone, lectin or growth factor.

25 P is preferably a monoclonal antibody of the IgG or IgM class, in particular a monoclonal antibody which is directed against an antigen which is present in dissolved form in body fluids or aqueous salt solutions or a monoclonal antibody which is directed against an antigen which is expressed on cells, in which case the cells expressing the antigen can be, in particular, cells of the myeloid or lymphatic system, cells of the peripheral blood, especially B lymphocytes, T lymphocytes or precursor cells thereof, or tumor cells, especially tumor cells

30

of the bone marrow. These cells can also be erythrocytes, bacteria, mycoplasmas or protozoa. However, viruses are also to be regarded as cells within the scope of the invention.

5 M is preferably a dispersible particle with a metal oxide core and an enveloping coat carrying amino groups, it being possible for a group of paramagnetic substances to be embedded in the metal oxide core, preferably a particle whose diameter is between about 0.1 μ and about 100 μ ,
10 but preferably between about 0.1 μ and about 1.5 μ .

The invention furthermore relates to a process for the preparation of a magnetic protein conjugate of the formula I and to the use of a conjugate of the formula I for the specific removal of cells or soluble antigens,
15 receptors, substrates, cofactors or carbohydrate determinants from aqueous salt solutions or body fluids, and to the use as part of a diagnostic aid or as a diagnostic aid, and, in particular, to the use for bone marrow depletion or for HLA typing.

20 A bone marrow transplantation is often the only therapeutic option, inter alia in the treatment of certain types of leukemia and of panmyelopathy (myelophthisis).

Patients with leukemias and certain lymphoid neoplasms are occasionally subjected to whole-body irradiation with
25 an extremely high dose and/or aggressive chemotherapy. Treatment of this type entails complete destruction of the normal stem cells of the bone marrow, the precursors of all blood cells. The patient therefore receives reinfusion of bone marrow from a suitable donor, from
30 which cells colonize the bone marrow cavities of the recipient and thus make it possible for the hemopoietic and immune system to develop anew. This method is called allogenic bone marrow transplantation.

The T lymphocytes of the donor which are transferred with

the reinfused bone marrow into the patient and which recognize the cells of the recipient as foreign, and therefore attack and destroy them, are responsible, inter alia, for the high risk associated with allogenic bone marrow transplantation. This bone marrow intolerance, which is often life-threatening for the patient, is called the graft-versus-host reaction or graft-versus-host disease (GVHD). The risks associated with this graft-versus-host disease can be reduced, on the one hand, by the patient being reinfused, where possible, with accurately typed bone marrow from particularly suitable donors, usually from among relatives. However, on the other hand, they can also be reduced by selective elimination of undesired cell populations as may be represented by, for example, T lymphocytes in the donor's bone marrow before reinfusion into the patient. This elimination of donor's T cells can be carried out, for example, by selective lysis of the cells which are to be removed in the presence of complement or by selective killing of the T cells using so-called immunotoxins or by another method, for example by magnetic cell depletion of the bone marrow.

Bone marrow cell depletion of this type can be carried out in a relatively straightforward manner by incubating the bone marrow with a murine monoclonal antibody which is, for example, directed specifically against the T cells of the bone marrow and, as a consequence, binds only to the T cells. Such T cells loaded with murine monoclonal antibodies can now be removed in a second step by incubating them, for example, with rabbit anti-mouse immunoglobulin which is bound to magnetic particles, which results in the T lymphocytes being loaded in a specific manner with the magnetic material so that they can be removed from the bone marrow using a magnet (see in this connection Vartdal et al., Transplantation (1987), 43, 366-371 and the literature cited therein).

It is also possible in an analogous manner to remove

5 other cell populations, such as tumor cells, from the
bone marrow, which is of importance for so-called autolo-
gous bone marrow transplantation (see in this connection
Kvalheim et al., Cancer Research (1987), 47, 846-851 and
the literature cited therein). This can also entail, as
described by Kvalheim et al., *ibid.*, the monoclonal
antibody which recognizes the tumor cells being directly
bound to the magnetic particles so that the above-
mentioned second antibody (rabbit anti-mouse) is no
10 longer required.

The method, described above, of bone marrow depletion
using monoclonal or polyclonal antibodies which are bound
to magnetic particles is still very new and requires
further development and testing. Magnetic particles
15 suitable for this purpose are now commercially available
in a wide variety of forms and the preparation thereof
has been described several times in the patent literature
(see, for example, Chagnon et al., EP 0125995 A2 (prior-
ity US 493991 of May 12, 1983), Advanced Magnetics, or
20 Ughelstad et al., WO 8303920 of Nov. 10, 1983, SINTEF).
It is known of these magnetic particles that they are
composed of a metal oxide core in which paramagnetic
substances can be embedded, and that the core is sur-
rounded by an enveloping coat which can carry reactive
25 groups such as, for example, aminophenyl, amino, car-
boxyl, hydroxyl or sulfhydryl groups which can be used
for coupling proteins (Chagnon et al., EP 0125995 A2).

It is known, for example, that particles carrying car-
boxyl groups can be reacted with amino groups of proteins
30 in the presence of a condensing agent (Chagnon et al., EP
0125995 A2).

It is furthermore known to couple proteins to magnetic
particles carrying amino groups by use of glutaraldehyde,
in which case the coupling takes place via the amino
35 groups in each case (Chagnon et al., EP 0125995 A2).

It is additionally known that particles carrying hydroxyl groups can be activated by reaction with p-toluenesulfonyl chloride and that particles activated in this way can be reacted with amino groups of proteins (Kvalheim et al., Cancer Research (1987), 47, 846-851).

It is common to all these coupling methods that the protein is attached to the particles in each case via its free amino groups. However, such coupling via amino groups can be a considerable disadvantage with monoclonal antibodies because this occasionally impairs the specificity and reactivity of the antibodies. This is a consequence of the fact that the amino groups in an antibody are, as it were, randomly distributed over the entire molecule and thus also located in the antigen-binding site of the Fab fragments, which brings about a loss of specificity on coupling via these amino groups.

It is additionally known that antibodies can also be picked up on magnetic particles purely by adsorption, without any chemical linkage, when the particles are composed of a styrene/divinylbenzene copolymer which contains iron oxide, because it is known that protein binds non-specifically to polystyrene.

However, impairment of the antibody specificity and reactivity must be expected with this method, too. Another serious disadvantage of this method is that, however, antibodies bound by adsorption become detached again on bone marrow depletion and thus may also be administered to the patient on reinfusion of the depleted bone marrow, which might lead to serious side effects, especially where there has been previous attempted therapy with monoclonal antibodies. However, this problem is known and is to be overcome by covalent attachment of the antibodies to the magnetic particles.

It is also known that polystyrene-based magnetic particles have the serious disadvantage that they tend to

aggregate and, moreover, attach themselves non-specifically to cells.

5 Starting from this state of the art, the object of the present invention is to develop a method in which monoclonal antibodies are coupled to magnetic particles
a) covalently and b) not via their amino groups. Hence, in other words, the object of the present invention is to find a coupling method in which the antigen-binding site of the antibody is not altered or the coupling of the
10 antibody takes place away from the antigen-binding site.

This object according to the invention is achieved by preparing magnetic protein conjugates of the formula I.



15 It has already been proposed to convert magnetic particles carrying amino groups into magnetic particles which carry as reactive groups maleimido functionalities, and to conjugate the latter with proteins which have
sulfhydryl groups, it being possible for the sulfhydryl groups in the protein to be either already present
20 naturally or introduced by chemical means or generated by reduction of disulfide linkages which are present.

It has now been found that magnetic particles which carry free amino groups as reactive groups can also be converted straightforwardly into magnetic particles which carry
25 iodoacetyl or bromoacetyl functionalities as reactive groups. Particles of this type are new.

It has additionally been found that magnetic particles which carry iodoacetyl or bromoacetyl functionalities can be conjugated without difficulty to proteins which have
30 sulfhydryl groups, it being possible for the sulfhydryl groups in the protein either to be already naturally present or introduced by chemical means or generated by reduction of disulfide linkages which are present.

5 It has been found, in particular, that magnetic particles
which carry iodoacetyl or bromoacetyl functionalities can
be conjugated without difficulty to monoclonal antibodies
when the interchain disulfide linkages of the antibodies
are converted by selective reduction into free SH groups
10 which can be induced to react with the iodoacetyl or
bromoacetyl functionalities of the magnetic particles
with the formation of a thioether linkage. This mode of
coupling monoclonal antibodies to magnetic particles is
likewise new.

15 It has been found, surprisingly, that the specificity and
reactivity of the antibodies coupled via thioether
linkages to magnetic particles is completely retained
because the coupling of the antibody via its hinge region
means that there is no alteration or impairment of its
antigen-binding site. This is responsible for a particu-
lar advantage of the invention compared with hitherto
disclosed coupling methods in which the antibodies are,
as described above, picked up on magnetic particles
20 either purely by adsorption or via reaction of their
amino groups, which may impair both the specificity and
the reactivity of the conjugated antibodies. Moreover,
the present invention has the advantage compared with
coupling by adsorption that the antibodies are chemically
25 bonded to the magnetic particles, and, as a consequence,
are not detached from the particles on use of magnetic
antibody conjugates according to the invention, for
example for bone marrow depletion.

30 It has additionally been found that the non-specific
adsorption of antibodies onto the magnetic particles
which takes place occasionally can be prevented or
reversed by addition of a suitable detergent.

35 It has additionally been found that the magnetic antibody
conjugates according to the invention prove to be parti-
cularly advantageous, because of their high specificity,
in the depletion of bone marrow, for example.

It has additionally been found that the magnetic antibody conjugates according to the invention also prove to be advantageous, because of their high specificity, as part of a diagnostic method or as a diagnostic aid, in particular, for example, in HLA typing.

5

The preparation of magnetic antibody conjugates according to the invention is described by way of example hereinafter for various monoclonal antibodies which are directed against cells of the bone marrow and for a polyclonal rabbit immunoglobulin; however, the said examples do not restrict the invention. In addition, the use of the prepared examples of magnetic antibody conjugates for the depletion of cells of the bone marrow is likewise described by way of example, without restricting the use to the said examples.


10

15

Process for the preparation of magnetic protein conjugates of the formula I:

20

Magnetic particles M which carry amino groups are reacted in a suitable solvent with a halogenoacyl spacer compound which reacts with amino groups and has the formula II



II

25

in which $n = 1$ or 2 and X is a chlorine, bromine or iodine atom, with the formation of an amide linkage to give a compound of the formula III



III

30

which is finally reacted in a suitable aqueous salt-containing solvent which does not denature proteins, such

as, for example, physiological saline solution or a phosphate-buffered saline solution, with a protein P carrying sulfhydryl groups, to give a compound of the formula I, after which the resulting compound of the formula I is washed free of any non-covalently bonded protein which is present with the addition of a suitable detergent such as, for example, Tween™.

Solvents suitable for the coupling of a compound of the formula II to magnetic particles must be of such a constitution that there is no impairment of the physical and magnetic properties of the magnetic particles used in each case for the coupling, in particular of the size, dispersibility and surface characteristics thereof, by the solvent which is used. An example of a solvent suitable for magnetic particles as are described, for example, in EP 0125995 A2 or WO 8303920 has been found to be a mixture of water and dimethylformamide.

Determination of the degree of coupling (μg of antibody/mg of iron)

Iron was determined by atomic absorption and nitrogen by the Kjeldahl method. The values for the coupled protein nitrogen were calculated by the formula

$$\frac{\mu\text{g P-N}}{\text{mg Fe}} = \frac{\mu\text{g Tot-N}}{\text{mg Fe}} (\text{sample}) - \frac{\mu\text{g Tot-N}}{\text{mg Fe}} (\text{control})$$

where the terms have the following meaning:

P-N: protein nitrogen
 Tot-N.: total nitrogen
 Fe: iron

The amount of protein bound to the particles (μg of protein/mg of iron) was calculated from the amount of protein nitrogen per mg of iron by multiplication by the factor 6.25. The calculated coupling rates are compiled

in Table 1.

Method for depletion of cells

5 A suspension of a cell mixture which is to be depleted in
a salt-containing, preferably physiological aqueous solu-
tion or in a body fluid is incubated with a compound of
the formula I at a suitable temperature between, for
example, 0°C and 40°C, preferably with shaking, likewise
preferably under sterile conditions, for a suitable
period, and then the magnetic particles are removed from
10 the solution by a suitable magnet.

Examples of suitable temperatures are 0°C, room tempera-
ture or 37°C, but room temperature is preferred. The
duration of the incubation depends in each case on the
incubation temperature used and on the binding reactivity
15 of the antibody and can be, for example, from a few
minutes up to, for example, two hours. Incubation is
preferably at, for example, room temperature for a period
of, for example, 10 to 20 minutes.

Method for the isolation of soluble bioorganic molecules

20 This method essentially follows the method for depletion
of cells.

Examples:

The examples which follow serve to illustrate the inven-
tion in detail, but do not restrict the invention.

25 Magnetic particles which have been reacted with mono-
clonal antibodies in the manner described are called
"magnetobeads" hereinafter, with their specificity being
indicated in each case by prefixing the particular
antibody name.

- 11 -

Example 1:

Conjugation of magnetic particles disclosed in EP 0125995
A2 with N-hydroxysuccinimidyl iodoacetate

5 4 x 300 μ l of a commercially available suspension of
magnetic particles (BioMag^R, Advanced Magnetics) were each
washed 3x with 10 ml of phosphate-buffered saline solu-
tion, pH 7.2, (PBS) each time and each were resuspended
in 3 ml of PBS. To each of these suspensions was added a
10 freshly prepared solution of 10 mg of N-hydroxysuccin-
imidyl iodoacetate (NHIA; Rector et al., J. Immunol.
Meth. (1978), 24, 321-336) in 2 ml of dry dimethyl-
formamide in each case, and the mixtures were shaken at
room temperature for 1 h. The particles were then removed
by centrifugation at 3000 x g, washed in each case 3x
15 with 10 ml of PBS each time and resuspended in a) 5 ml,
b) 4.3 ml, c) 3.6 ml and d) 2.9 ml of PBS pH 7.2.

Example 2:

Conjugation of magnetic particles disclosed in EP 0125995
A2 with N-hydroxysuccinimidyl bromoacetate

20 Conjugation was carried out in analogy to Example 1 with
N-hydroxysuccinimidyl bromoacetate (NHBrA), the NHBrA
being prepared in analogy to the preparation of NHIA by
the method of Rector et al., *ibid.*

Example 3:

25 Coupling of polyclonal rabbit anti-mouse immunoglobulin
(RAM) to particles activated as in Example 1

30 3 mg of polyclonal rabbit anti-mouse immunoglobulin in
phosphate-buffered saline solution (500 μ l) were mixed
with 3 mg of dithiothreitol and incubated at room temper-
ature for 30 min. The reduced antibody was isolated by
gel filtration through SephadexTM G25 in phosphate-buffered

saline solution, pH 7.2, in an elution volume of 4.2 ml and added to the particle suspensions a-d prepared as in Example 1, as follows:

- a: no addition (control)
- 5 b: addition of 0.7 ml (about 0.5 mg of protein)
- c: addition of 1.4 ml (about 1.0 mg of protein)
- d: addition of 2.1 ml (about 1.5 mg of protein)

10 The mixtures (5 ml each) were each incubated with shaking at room temperature for 1 h. The particles were then removed by centrifugation at 3000 x g, washed 3x with 10 ml of PBS each time, resuspended in 5 ml of PBS pH 7.2, and stored at 4°C. The analytical data are compiled in Table 1.

Example 4:

- 15 Coupling of polyclonal rabbit anti-mouse immunoglobulin (RAM) to particles activated as in Example 2.

Coupling was carried out in analogy to Example 3. The analytical data are compiled in Table 1.

Example 5:

- 20 Coupling of the monoclonal antibody BMA 081 (anti-CD8; IgG2a) to particles activated as in Example 1

25 2 mg of BMA 081 in PBS (500 μ l) were mixed with 1 mg of dithiothreitol and incubated at room temperature for 30 min. The reduced antibody was isolated by gel filtration through Sephadex G25 in phosphate-buffered saline solution, pH 7.2, in an elution volume of 3.6 ml and added to the particle suspensions a-d prepared as in Example 1, as follows:

- a: no addition (control)
- 30 b: addition of 0.4 ml (about 0.2 mg of protein)
- c: addition of 1.2 ml (about 0.6 mg of protein)
- d: addition of 2.0 ml (about 1.0 mg of protein)

- 13 -

The mixtures (about 5 ml each) were each incubated with shaking at room temperature for 1 h. The particles were then removed by centrifugation at 3000 x g, washed 3x with 10 ml of PBS each time, resuspended in 5 ml of PBS pH 7.2, and stored at 4°C. The analytical data are compiled in Table 1.

Example 6:

Coupling of the monoclonal antibody BMA 0110 (anti-CD2; IgG2b) to particles activated as in Example 1

The coupling was carried out in analogy to Example 5. The analytical data are compiled in Table 1.

Example 7:

Depletion of CD8⁺ cells from mononuclear cells using magnetobeads prepared as in Example 5

Mononuclear cells (MNC) were isolated from freshly donated human blood in a manner known per se (Boyum, Scand. J. Immunol. (1976), Suppl. 5, 9 - 15) on a Ficoll gradient.

For the depletion, 3 x 10⁷ MNC in 2 ml of PBS containing 1% BSA (w/v, Seromed™) in plastic tubes (Falcon™, No. 2051) were mixed with 1 ml of a suspension of 2 mg/ml magnetobeads in PBS and incubated at room temperature, shaking continuously, for 15 min. The magnetobeads prepared as in Example 5 and the cells bound thereto were then removed using a permanent magnet. The cells remaining in suspension were pelleted at 400 x g and resuspended in a suitable medium, for example PBS or RPMI 1640. The depletion efficiency was determined by indirect immunofluorescence in a cytofluorograph (Ortho).

For this purpose, 1 x 10⁶ cells were, before and after depletion of a defined cell population, labeled with

1 $\mu\text{g/ml}$ first antibody BMA 031 (Behringwerke AG) and then with 20 $\mu\text{g/ml}$ second antibody (rabbit anti-mouse immunoglobulin, F(ab)_2 fragment, FITC-labeled, Behringwerke) in a manner known per se and evaluated in a cytofluorograph, where the depletion efficiency was determined to be above 95 %.

5

Table 1:

Degrees of coupling of various prepared magnetobeads

Example	Antibody	Isotype	Coupling method	Coupling ratio Protein/iron ($\mu\text{g}/\text{mg}$)
3b	RAM	poly	NHIA	74
3c	RAM	poly	NHIA	136
3d	RAM	poly	NHIA	171
4b	RAM	poly	NHBrA	98
4c	RAM	poly	NHBrA	143
4d	RAM	poly	NHBrA	167
5b	BMA 081	IgG2a	NHIA	56
5c	BMA 081	IgG2a	NHIA	107
5d	BMA 081	IgG2a	NHIA	113
6b	BMA 0110	IgG2b	NHIA	76
6c	BMA 0110	IgG2b	NHIA	156
6d	BMA 0110	IgG2b	NHIA	183

RAM: rabbit anti-mouse immunoglobulin

poly: polyclonal

NHIA: N-hydroxysuccinimidyl iodoacetate

NHBrA: N-hydroxysuccinimidyl bromoacetate

- 16 -

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A magnetic protein conjugate of the formula I



wherein $n = 1-6$ and M is a dispersible, magnetically reacting material or particle which carries amino groups, and P is a protein.

2. A magnetic conjugate as claimed in claim 1, wherein $n=1$ or 2.
3. A magnetic conjugate as claimed in claim 2, wherein $n=1$.
4. A magnetic protein conjugate as claimed in claim 1, wherein S in Formula I is a sulfhydryl group or groups of the protein P that are either present in the natural way or generated by reduction of disulphide linkage or introduced by chemical reaction into the protein.
5. A magnetic protein conjugate as claimed in claim 1, wherein P is a polyclonal immunoglobulin.
6. A magnetic protein conjugate as claimed in claim 1, wherein P is a monoclonal antibody or a Fab, Fab' or F(ab')_2 fragment.
7. A magnetic protein conjugate as claimed in claim 1, wherein P is an antigen or a residue of an enzyme, hormone, lectin or growth factor.


8. A magnetic protein conjugate as claimed in claim 6, wherein P is a monoclonal antibody of the IgG or IgM class.
9. A magnetic protein conjugate as claimed in claim 6, wherein P is a monoclonal antibody which is directed against an antigen which is present in dissolved form in aqueous salt solutions or body fluids.
10. A magnetic protein conjugate as claimed in claim 6, wherein P is a monoclonal antibody which is directed against an antigen which is expressed on cells.
11. A magnetic protein conjugate as claimed in claim 10, wherein the said monoclonal antibody is directed against an antigen which is expressed on cells of the myeloid or lymphatic system.
12. A magnetic protein conjugate as claimed in claim 10, wherein the said monoclonal antibody is directed against an antigen which is expressed on cells of the peripheral blood.
13. A magnetic protein conjugate as claimed in claim 10, wherein the said monoclonal antibody is directed against an antigen which is expressed on B lymphocytes, T lymphocytes or the precursor cells thereof.
14. A magnetic protein conjugate as claimed in claim 10, wherein the said monoclonal antibody is directed against an antigen which is expressed on tumour cells.
15. A magnetic protein conjugate as claimed in claim 10, wherein the said monoclonal antibody is directed against an antigen which is expressed on tumour cells of the bone marrow.

- 18 -

16. A magnetic protein conjugate as claimed in claim 6, wherein P is a monoclonal antibody which is directed against an antigen which is expressed on bacteria, mycoplasmas or protozoa or else on viruses.
17. A magnetic protein conjugate as claimed in claim 1, wherein P is an antigen.
18. A magnetic protein conjugate as claimed in claim 1, wherein M is a disperisible particle with a metal oxide core and an enveloping coat carrying amino groups, it being possible for a group of paramagnetic substances to be embedded in the metal oxide core.
19. A magnetic protein conjugate as claimed in claim 18, wherein the diameter of the particles is between about 0.1μ and about 100μ .
20. A magnetic protein conjugate as claimed in claim 19, wherein the diameter of the particles is between about 0.1μ and about 1.5μ .
21. A process for the preparation of a magnetic protein conjugate of the formula I where $n = 1-6$,




which comprises magnetic particles M which carry amino groups being reacted with a halogenocyl spacer which reacts with amino groups and has the formula II



- 19 -

in which n has the said meaning, and X is a chlorine, bromine or iodine atom, with the formation of an amide linkage to give a compound of the formula III




which is finally reacted with a protein P carrying sulfhydryl groups to give a compound of the formula I, after which the resulting compound of the formula I is washed free of non-covalently bonded protein.

22. A compound of the formula III




in which M and n have the meaning specified in claim 1, and X is a chlorine, bromine or iodine atom.

23. A method for removing a dissolved antigen, antibody, receptor, substrate, cofactor or carbohydrate determinant from aqueous salt solutions or body fluids, which comprises the solution being incubated with a suitable magnetic protein conjugate of the formula I



in which M, P and n have the meaning specified in claim 1 and, after specific adsorption of the component which is to be removed, the magnetic protein conjugate being separated out by magnetic means, and the specifically adsorbed component being, where appropriate, eluted again from the magnetic protein conjugate.

24. A method for removing cells from aqueous salt solutions or body fluids, which comprises the cell suspension being incubated with a suitable magnetic protein conjugate of the formula I



in which M, P and n have the meaning specified in claim 1 and, after specific adsorption of the cells which are to be removed, the magnetic protein conjugate being separated out by magnetic means, and the specifically adsorbed cells or particles being, where appropriate, detached again from the magnetic protein conjugate.

25. The use of a magnetic protein conjugate as claimed in claim 1 for the specific removal of cells or soluble antigens, receptors, substrates, cofactors or carbohydrate determinants from aqueous salt solutions or body fluids or the use as part of a diagnostic method or as a diagnostic aid.
26. The use of a magnetic protein conjugate as claimed in claim 1 for removing cells as claimed in any one of claims 10-16.
27. The use of a magnetic protein conjugate as claimed in claim 26, wherein the use is for bone marrow depletion.
28. The use of a magnetic protein conjugate as claimed in claim 26, wherein the use is for HLA typing.